ArticleACS medicinal chemistry letters2025
Unraveling the Potential Pathogenic Role of Squalene Synthase (SQS) in Lung Cancer Using Enzyme Inhibitors as Molecular Tools.
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squalene synthase (SQS) is a key enzyme in the mevalonate pathway, catalyzing the first committed step in cholesterol biosynthesis. Several small-molecule SQS inhibitors have been developed thus far, initially aiming at treating hypercholesterolemia. Although their development for cardiovascular diseases was limited after clinical trials compared with statins, the potential of SQS as an anticancer target has recently gained renewed attention. Nevertheless, the evaluation of SQS inhibitors as anticancer agents has been rudimentary thus far. Herein, we attempted to provide some clear evidence of the potential of this enzyme as a "druggable" target in lung cancer. Accordingly, two chemically diverse SQS inhibitors were used as pharmacological tools and tested in different cancer-cell-based assays, providing some groundwork for their mechanistic underpinning in cancer cells. Lastly,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.